iShares Evolved U.S. Innovative Healthcare ETF (IEIH)

For informational purposes only. Not financial advice.

Quick Answer

iShares Evolved U.S. Innovative Healthcare ETF (IEIH) has a 0.18% expense ratio and $37M in assets under management. Holdings and weights below are as of Mar 15, 2026.

In the stored portfolio snapshot, the largest listed holding is Johnson & Johnson (JNJ) at 10.24%, and the largest sector allocation is Healthcare at 99.9%.

iShares Evolved U.S. Innovative Healthcare ETF (IEIH) ETF — Price, Holdings & Analysis

ETF Overview

IEIH aims to provide investors with exposure to U.S. listed companies in the innovative healthcare sector. The fund invests at least 80% of its net assets in the common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. IEIH focuses on companies that fall into the Innovative Healthcare Evolved Sector, selecting those with economic characteristics historically correlated with traditional pharmaceutical and biotechnology companies. This approach results in a concentrated portfolio; the fund currently. The top holdings include Johnson & Johnson (10.24%), Eli Lilly and Co (7.55%), and AbbVie Inc (6.08%). With nearly all of its assets (99.9%) allocated to the Healthcare sector, IEIH offers a targeted investment vehicle for those seeking exposure to innovative healthcare companies. The fund is non-diversified, which means it invests a larger percentage of its assets in a smaller number of issuers than a diversified fund.

Risk Metrics

IEIH presents several risk considerations for investors. The fund's non-diversified status and small number of holdings (8) results in significant concentration risk; a downturn in any one of its top holdings could have a substantial negative impact on performance. Sector risk is also elevated, as nearly all (99.9%) of the fund's assets are allocated to the Healthcare sector, making it vulnerable to sector-specific headwinds. With a 3-year beta of 0.58, IEIH has historically exhibited lower volatility than the broader market. The fund's expense ratio of 0.18% will create a slight drag on returns over time, but is relatively low. Past performance does not guarantee future results.

Beta: 0.58

Expense Ratio

0.18%

What does IEIH hold?

Holding	Weight
Johnson & Johnson (JNJ)	10.24%
Eli Lilly and Co (LLY)	7.55%
AbbVie Inc (ABBV)	6.08%
Merck & Co Inc (MRK)	5.77%
Bristol-Myers Squibb Co (BMY)	5.36%
Vertex Pharmaceuticals Inc (VRTX)	5.13%
Amgen Inc (AMGN)	4.38%
Moderna Inc (MRNA)	4.33%
Gilead Sciences Inc (GILD)	4.01%
Regeneron Pharmaceuticals Inc (REGN)	3.96%

Holdings and weights as of Mar 15, 2026. This fund data is more than 45 days old; verify current holdings with the issuer.

How Is the Fund Allocated?

Sector	Weight
Healthcare	99.9%
Technology	0.1%
Communication Services	0.0%

Country	Weight
United States	49.6%
Other	50.4%

Dividend Yield

1.34%

ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
iShares MSCI EAFE ETF (EFA) — 0.32% expense ratio

iShares iBoxx $ High Yield Corporate Bond ETF (HYG) (Fixed Income) — 0.49% expense ratio
iShares 20+ Year Treasury Bond ETF (TLT) (Fixed Income) — 0.15% expense ratio
iShares MSCI Emerging Markets ETF (EEM) (Equity) — 0.72% expense ratio
iShares MSCI UAE ETF (UAE) (Equity) — 0.59% expense ratio
iShares Climate Conscious & Transition MSCI USA ETF (USCL) (Equity) — 0.08% expense ratio

Questions & Answers

What is IEIH and what does it track?

The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is an exchange-traded fund that seeks to track the performance of U.S. listed innovative healthcare companies.

The fund invests primarily in common stock of pharmaceutical and biotechnology companies, focusing on those with economic characteristics historically correlated with the sector.

What is the expense ratio for IEIH?

The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) has an expense ratio of 0.18%. This means that for every $10,000 invested in the fund, $18 is deducted annually to cover operating expenses.

While expense ratios can vary widely among ETFs, IEIH's 0.18% is relatively low compared to the average expense ratio for equity ETFs, which hovers around 0.44%.

What are the top holdings in IEIH?

As of 2026-03-15, the top holdings in the iShares Evolved U.S. Innovative Healthcare ETF (IEIH) are concentrated in a few key companies.

The top three holdings are Johnson & Johnson (JNJ) at 10.24%, Eli Lilly and Co (LLY) at 7.55%, and AbbVie Inc (ABBV) at 6.08%.

Is IEIH a good long-term investment?

Whether IEIH is a suitable long-term investment depends on an individual investor's risk tolerance, investment objectives, and time horizon. IEIH offers targeted exposure to the innovative healthcare sector, which may present growth opportunities.

However, the fund's concentrated portfolio and sector-specific focus also introduce risks. With a 3-year beta of 0.58, IEIH has historically exhibited lower volatility than the broader market.

How does IEIH compare to similar ETFs?

IEIH differentiates itself through its evolved sector approach and concentrated portfolio. Many healthcare ETFs offer broader diversification across the healthcare industry, while IEIH focuses specifically on innovative healthcare companies.

The fund's expense ratio of 0.18% is competitive within the healthcare ETF landscape.

Does IEIH pay dividends?

Yes, the iShares Evolved U.S. Innovative Healthcare ETF (IEIH) does pay dividends. As of 2026-03-15, the fund has a dividend yield of 1.34%.

This means that for every $100 invested in the fund, investors can expect to receive $1.34 in dividend payments annually. It's important to note that dividend yields can fluctuate over time and past dividend payments do not guarantee future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.